FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from an interim analysis of its pivotal, Phase 3 PURPOSE 1 trial indicating that the ...

The federal Food and Drug Administration October 3 approved a new daily PrEP pill that could offer a safer option for some individuals at risk for HIV, but the indication does not cover everyone who ...

In it, the safety and efficacy of a twice-yearly, under-the-skin (subcutaneous) injection of lenacapavir for PrEP was compared with once-daily oral Descovy or Truvada in more than 5,300 cisgender ...

A new HIV prevention option works well for gay and bisexual men and transgender women and should be approved by the Food and Drug Administration for these populations, according to an expert advisory ...

Gilead Sciences, Inc. GILD announced upbeat top-line results from an interim analysis of its late-stage study PURPOSE 1. PURPOSE 1 is a phase III, double-blind, randomized study evaluating the safety ...

Gilead Sciences is coming off of a milestone year that saw the start of the much-anticipated launch of the world’s first twice-yearly injectable HIV pre-exposure prophylaxis (PrEP) medicine Ye | ...

A Gilead Sciences drug that protects against HIV infection has won a highly anticipated FDA approval, becoming the first medication for HIV prevention available as a twice-yearly injection. The ...

(Reuters) - An FDA advisory panel on Wednesday voted in favour of Gilead Sciences Inc's combination drug to reduce the risk of sexually acquired HIV infection in men and transgender women who have sex ...

As Gilead Sciences tussles with a web of HIV drug litigation, a high-stakes case tied to patents for prevention medicines is coming back to test the drugmaker. On Friday, the U.S. Department of ...